Transcatheter aortic valve replacement: A total of 500 consecutive patients with NAVR undergoing TAVR will be enrolled at 3-5 centers. Clinical follow-up will be conducted in the periprocedural and after aortic valve implantation at 1 month, 1 year, 2 years, 3 years, 4 years, 5 years, and 10 years
Study summary
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1\. Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.
* 2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form
Exclusion Criteria:
* 1\. Patients who cannot provide informed consent
* 2\. Patients who are treated with TAVR for aortic stenosis
* 3\. Patients who are participating in other clinical trials
Primary outcome measure(s)
Combined clinical efficacy outcomes — 1 year Combined clinical efficacy outcomes as composed by all-cause mortality, all strokes, any hospitalization
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.